To read more on these records and others in the pharmaceutical arena, please visit Clarivate Analytics Cortellis, where you may access full pdf documents of the same, along with expert analysis and indexing of their content to accompany detailing of such aspects as expirations, infringements, licensing and exclusivity.
The Patent Gazette provides snapshot analysis and indexing of pharmaceutically relevant patenting within days of its publication by patent offices. Primarily focusing on material from the main three patents offices (i.e., the EPO, USPTO, and WIPO), it provides brief descriptions of a patent’s content and seeks to link it to both prior patenting of relevance and to any commercial activity pertinent to the technology being described.
Subscription and access to Cortellis may be tailored and restricted to particular subject areas of interest, such as only its patenting content. For more details please do contact us.
WO2020102756-A1: “Nasal neurostimulator with integrated RFID.”
Assignee: Allergan USA Inc; Oculeve Inc
Inventors: Baldwin, Jarren, A.; Dhananjayan, Nithin; Wardle, John
IPC Codes: A61N 1/378; A61N 1/36; G06K 19/07; A61N 1/05; A61N 1/375; A61N 1/18
Publication Date: 22-May-2020 (also published as US20200155831-A1, 21-May-2020)
Earliest Priority Details: US2018768685, 16-Nov-2018
Handheld stimulator system with an integrated radio-frequency identification (RFID) control mechanism that is useful for stimulating the nasal or sinus tissue of a subject to increase tear production, reduce the symptoms of dry eye, or improve ocular appearance and/or health. The system comprises nasal stimulator probes in the form of nasal insertion prongs comprising electrodes, which may be configured to be at least partially inserted into the nasal cavity and deliver an electrical stimulus to nasal or sinus tissue.
Published WO2020102754-A2, entitled, “Nasal neurostimulation device with electrically conductive plastic electrode”. For prior patenting in which Oculeve’s founder, Michael Ackermann, describes extra-nasal stimulation devices for treating dry eye through the delivery of electrical or ultrasonic stimulation to facial tissue, see WO2018102778.
In August 2015, Allergan completed its acquisition of Madison, New Jersey-based Oculeve, gaving it access to the Stanford Biodesign start-up’s dry eye research and development programs including OD-01 - a non-invasive nasal neurostimulation device that increases tear production. Rebranded as the TrueTear® Intranasal Tear Neurostimulator, the device gained US FDA approval in April 2017 for use in temporarily increasing tear production during neurostimulation in adult patients.
WO2020102573-A1: “Non-invasive monitoring system.”
Assignee: AerBetic Inc
Inventors: Cooper, Lloyd; Fitzgerald, Matt; Housh, Eric; Thors, Arnar
IPC Codes: A61B 5/00; A61B 5/1477
Publication Date: 22-May-2020
Earliest Priority Details: US2018760981, 14-Nov-2018
A wearable device for non-invasive monitoring of an analyte in a sample from a user that may be indicative of hypoglycemia, infection, respiratory infection, urinary infection, gastrointestinal infection, obesity, diabetes, type I diabetes or type II diabetes. It is claimed that the analyte may be a volatile organic compound (VOC), and that the sample may be an indirect sample (eg a user breathing through a tube into an inlet port of the device) or ambient air emanating from the user. Within the disclosure and imagery, we see an embodiment in which the wearable device is worn on the wrist with inlet ports around the rim of the watch-like device’s face being able to draw samples of air to test for the presence of VOCs. In other embodiments, the wearable device may be worn around the neck, attached to an article of clothing, or placed adjacent to a region of the body and worn underneath clothing.
Represents the first patenting from Birmingham, Alabama-based AerBetic Inc that demonstrated its non-invasive, wearable diabetes alert system at the 2019 Consumer Electronics Show in Las Vegas. The device contains nano-sensors (designed and manufactured by San Diego, California-based AerNos™) that detect gases given off through breath or skin, that are symptomatic of high or low blood sugar. It will pair with smartphone apps, aiding the ability to push alerts to patients and caregivers. The inventor and AerBetic CEO Arnar Thors was inspired to create his wearable device by those diabetes alert dogs that are trained to use their acute sense of smell to alert their owners early of a peak or dip in blood sugar before it becomes dangerous.
US20200155250-A1: “Systems and methods for autonomous cardiac mapping.”
Assignee: Boston Scientific Scimed Inc
Inventors: Ghodrati, Alireza; Salehi, Leili
IPC Codes: A61B 34/20; G06N 20/00; A61B 5/06; A61B 34/32
Publication Date: 21-May-2020
Earliest Priority Details: US2018770156, 20-Nov-2018
System for autonomous cardiac mapping of a heart chamber, comprising a processor configured to acquire a representative geometric shell of the heart chamber, control a robotic device to autonomously navigate a mapping probe to a plurality of locations within the heart chamber based at least in part on the representative geometric shell, and generate a three-dimensional (3D) electroanatomical map of the heart chamber based on electrical data collected by the probe.
Within the application it discloses how mapping the electrophysiology of heart rhythm disorders may be performed using a mapping probe (namely, Boston Scientific’s ORION™ high resolution mapping catheter), processing system, display and navigation processor that are components of Boston Scientific’s RHYTHMIA™ mapping system. The system automatically identifies one or more regions of the heart chamber and interprets the generated electroanatomical map for performing a substrate analysis of the heart chamber, and an automatic interpretive algorithm such as Boston Scientific’s LUMIPOINT™ computer software can be used to perform said substrate analysis.
Boston Scientific launched the RHYTHMIA™ mapping system in 2012, and an updated RHYTHMIA HDx™ mapping system was launched at Heart Rhythm Society (HRS) 2017 annual meeting. It can show lower voltages than on previous-generation mapping systems and uses a 64-electrode basket catheter to create very detailed, high-density electro-maps with as many as 50,000 to 60,000 points.
Follows a pair of co-published applications from one of the inventors, Ghodrati, describing systems and methods for mapping electrical activity in the heart, see US20190216346 and US20190216347.
WO2020102629-A1: “Thermally controlled residence devices.”
Assignee: Brigham & Women’s Hospital; Massachusetts Institute of Technology
Inventors: Babaee, Sahab; Langer, Robert, S.; Pajovic, Simo; Shi, Jiuyun; Traverso, Carlo, Giovanni
IPC Codes: A61M 31/00; A61M 5/142; A61L 31/16
Publication Date: 22-May-2020 (also published as US20200155821-A1, 21-May-2020)
Earliest Priority Details: US2018767749, 15-Nov-2018
Thermally controlled gastric residence devices (GRDs). The inventors report how administering warm fluid orally results in two heat zones within a subject. Namely, an esophageal zone that experiences large temperature fluctuations and an extra-esophageal compartment, eg the stomach, that does not experience large temperature fluctuations with the ingestion of warm fluids were identified. They recognized that the existence of these different temperature regions may permit the use of temperature-based control for medical devices intended for use in the gastrointestinal tract.
When the device has served its purpose, elevated temperatures may be used to selectively weaken and/or disassemble the device to facilitate its removal by breaking it down into smaller fragmented portions that can naturally pass out of, or otherwise be removed from, the stomach. One means by which an elevated temperature may be applied to the device would be by warm water being sprayed onto the individual couplings of the device using an endoscopic device. In another, a conductive material, such as a metallic powder, may be incorporated into the couplings of a residence device such that the couplings can interact with an applied varying electromagnetic field to enable radiofrequency heating, using a radiofrequency source located outside of the subject.
The disclosed GRDs have the potential to house large therapeutic compound depots (in the multigram range) for the treatment of infections and other conditions where prolonged therapy may be desired. Other potential clinical applications it states may include nutritional modulation for bariatrics and obesity treatment. The devices may also include electrical capabilities to sense a range of signals to facilitate mobile health and the monitoring of patients suffering from chronic conditions where early detection of a signal such as bleeding or a fever could considerably enhance the capacity to intervene. Within the invention’s examples we see the devices being used for the delivery of the epilepsy treatment carbamazepine, and the tuberculosis treatment moxifloxacin.
Published alongside WO2020102648-A1 in which Langer, Traverso, Babaee and Pajovic describe millineedle systems for esophageal drug delivery. Langer (the David H Koch Institute Professor at MIT and a member of the Koch Institute for Integrative Cancer Research) and Traverso (an Assistant Professor in MIT’s Department of Mechanical Engineering and a gastroenterologist at Brigham and Women’s Hospital) previously described a GRDs capable of transesophageal administration, transesophageal retrieval, and/or gastric retention in WO2019232291.
Langer and Traverso founded a Watertown, Massachusetts-based start-up called Lyndra in 2015 to commercialize their development of a pill designed to continuously release one or more drugs in a patient’s stomach over the course of a week or longer. After a patient swallows it, the outer capsule dissolves and the pill opens up into a star shape, which prevents it from being passed. It remains in the gastrointestinal tract for a predetermined time, such as a week or a month, all the while releasing the drug from the star’s prongs. After which the prongs’ specially designed disintegrating matrices break down, allowing safe passage through the lower gastrointestinal tract. As evidenced from the present patent application, the researchers are continuing to experiment with mechanisms to trigger the arms to break off and enable excretion such as pH or temperature change as well as perhaps exposure to a particular chemical. The span of the Lyndra device is about 5.4 cm, while the human pylorus is about 1.7 to 1.9 cm.
WO2020101707-A1: “Devices and systems for intraluminal local drug delivery.”
Assignee: ConvergAscent LLC
Inventors: Craig, Brian, H
IPC Codes: A61M 25/10; A61B 5/00; A61M 25/00
Publication Date: 22-May-2020
Earliest Priority Details: WO2018US61607, 16-Nov-2018
The application describes a catheter with two optionally expandable regions and ports in the catheter between the two expandable regions. The catheter is inserted into a body lumen at a point requiring treatment with drug, the two expandable regions are expanded to isolate the lumen between them from the rest of the patient, then drug solution is passed via one of the ports into the volume between the expanded regions to treat the affected tissue. Once done, the drug solution may be removed via the catheter and the expanded regions collapsed before removal.
ConvergAscent has given rise to two start-up companies, Elements Endoscopy and Isola Therapeutics. Isola is described as developing local drug delivery systems for the treatment of cancer while reducing systemic toxicity. It seems possible that the present invention may be developed by Isola.
This application continues from WO2019099036 on devices for intraluminal drug delivery.
WO2020102695-A1: “Thermally regulated transdermal drug delivery system.”
Assignee: CTI (assignment for benefit of creditors) LLC
Inventors: Ruane, Patrick, H; Hancock, Jackie, Joe; Arora, Anubhav
IPC Codes: A61K 9/00; A61N 1/02; A61F 13/00
Publication Date: 22-May-2020
Earliest Priority Details: US2018768768, 16-Nov-2018
The application describes a transcutaneous or transmucosal delivery system where drug is contained in a transdermal membrane and the membrane may be heated or cooled to control the delivery of drug to the patient. Drug may thereby be delivered in pulses. The application appears to focus particularly on the delivery of nicotine to treat smoking addiction and drugs for the treatment of Parkinson’s disease.
Two of the team have appear on filings to the Foundry Corporation describing depots for the controlled release of analgesics (see eg WO2019071246, ‘243, and ‘245).
This appears to be the first application from CTI.
EP3653252-A1: “A device for the care of respiratory wellbeing and for training and the improvement of respiratory function.”
Assignee: Hapella Oy
Inventors: Kuronen, Ilpo; Naghian, Siamäk
IPC Codes: A61B 5/00; A61M 11/04; A61B 5/091; A61B 5/087; A61M 16/10; A61M 16/16; A61M 16/20; A63B 21/008; A63B 23/18; A63B 21/00
Publication Date: 20-May-2020 (also published as US20200155898-A1, 21-May-2020, and FI128346-B, 31-Mar-2020)
Earliest Priority Details: FI20185974, 19-Nov-2018
Method and a system for monitoring and controlling air and steam flows and temperature in a device comprising at least a first flow channel and a space liquid space. The device is useful for patients with respiratory diseases such as COPD and asthma.
The inventor Ipo Kuronen is the University of Eastern Finland’s Business Development Manager, and Scientific Advisor to and former CEO of Kuopio, Finland-based Hapella Oy that has developed a respiratory care device called WellO2 that it believes promises benefits for a wide range of individuals, including asthmatics, athletes, or those suffering from a cold.
The respiratory training device combines resistive breathing and warm vapor inhalation to support better and more efficient breathing. When you blow into the device, the resistance created opens up the airways so when you inhale the warm vapor, it gets deeper into the airways. A combination that the company says opens up the airways and clears mucus, while breathing against resistance trains the respiratory muscles. Hapella believes this can help not only those with acute or chronic breathing difficulties, but also shallow breathers, snorers, the elderly and even athletes by increasing chest mobility, lung capacity and enhancing blood circulation.
For prior patenting in which the Hapella’s founder Aulis Kärkkäinen described his WellO2 device, see WO2014041047. Having suffered himself with respiratory difficulties and asthma, Kärkkäinen had always found the steam in a sauna helped relieve his condition, but it was not until 2010 when he tried resistive breathing that he realized what a powerful effect combining the two could have.
WO2020102439-A1: “Wearable systems, devices, and methods for measurement and analysis of body fluids.”
Assignee: Nix Inc
Inventors: Cochran, Brett; Mishra, Shawn; Ritsher, Kenneth; Roberts, Michael; Tonderys, Daniel; Unger, Meridith
IPC Codes: G01N 33/487; A61B 5/145; A61B 5/00
Publication Date: 22-May-2020
Earliest Priority Details: US2018760202, 13-Nov-2018
Wearable sample analysis system configured to collect a sample of bodily fluid, and measure and analyze the bodily fluid to determine a property of the bodily fluid and/or a health parameter of the wearer (eg degree of hydration, electrolyte losses, or perspiration rate). Within the application’s disclosure and imagery, we see the sample handing device being represented as a disc positioned on the surface of the user’s skin. The disc is configured to collect sweat from the user that can then be measured and analyzed in near real-time while the user engages in an activity. It also states that the sample analysis systems and sample handling device can be used without being attached to the user and can be used for analyzing any number of other bodily fluids.
Represents the first patenting to have emerged in the name of the Harvard Launch Lab-based Nix Inc. The inventor Meridith Unger is founder and CEO of the company whose initial product is a wearable hydration sensor to be aimed at the consumer fitness and military markets. She was reportedly working for Boston Children’s Hospital’s Technology Development Fund when the idea behind Nix first began to form. There she had been working on a wearable dehydration diagnostic device for the emergency room, where doctors were still measuring dehydration by the traditional method of pinching a child’s fingernail and waiting to see how long it took for the color to return. This led to her development of Nix’s non-invasive sensors that can read biomarkers present in bodily fluids such as sweat, saliva, tears, and even breast milk.
WO2020102821-A1: “Systems and methods related to syringes.”
Assignee: Plas-Tech Engineering Inc
Inventors: Hirschmann, Aaron; Fesus, Robert
IPC Codes: A61M 5/19; A61M 5/315; A61M 5/50; A61M 5/00
Publication Date: 22-May-2020
Earliest Priority Details: US2018768230, 16-Nov-2018
The application describes a single-use zero or near zero dead volume syringe. The plunger of the syringe is narrower at its tip than the bore of the syringe, allowing the plunger to be fitted with a thin flexible cap. The dimensions of the plunger tip, cap, syringe bore and channel connecting the syringe bore to the needle or other device taking delivery of the drug solution are such that the cap forms a seal with the inside of the tip of the syringe bore but can still pass through the channel when the syringe is in use. In this way maximum delivery of drug is achieved. Once through the channel, the cap opens and prevents the plunger from being pulled back into the syringe. In this way, single use is achieved.
The company appears to make only products for the medical industry, and is FDA registered.
The application continues the company’s interests in developing syringes, see eg US20180263852 on a syringe assembly.
US20200155872-A1: “Low-intensity pulsed ultrasound for treatment of depression.”
Assignee: University of Alberta
Inventors: Chen, Jie; Li, Xinmin
IPC Codes: A61N 7/00; A61M 21/02
Publication Date: 21-May-2020 (also published as CN111184950-A, 22-May-2020)
Earliest Priority Details: US2018767635, 15-Nov-2018
Portable low-intensity pulsed ultrasound (LIPUS) therapy device for use in treating mental health disorders, and depression in particular, comprising a wearable headband with at least one transducer element, and a controller for causing the transducer to produce LIPUS.
A Professor in the University of Alberta’s Faculty of Engineering - Electrical & Computer Engineering Department, Dr Chen has had a paper entitled, “Safety Assessment of a Wearable Low-Intensity Pulsed Ultrasound Device for Relieving Mental Illness Symptoms”, accepted by the 42nd Annual International Conferences of the IEEE Engineering in Medicine and Biology Society that is scheduled for July 2020 in Montreal, Canada. The paper’s abstract reports how his wearable head-mounted LIPUS device was assessed for potential tissue damage when applying LIPUS stimulation on the brain. Results from computer simulations and in-vitro experiments demonstrated that the LIPUS device could safely deliver small doses of LIPUS through the skull into the brain - indicating the modality has potential for use in the treatment of neurological diseases in the future.
For prior patenting in which Dr Chen described a LIPUS device that could be used to stimulate stem cells, and non-invasively and safely enhance dental tissue healing and/or stimulate bone growth, see WO2007131337.